Oramed Pharmaceuticals Inc. — Director's Dealing 2023

May 1, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2023-05-01

Reporting Person: Shapiro Benjamin (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-01	Common Stock	A	20000	—	Acquired	20000	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1900000	Indirect

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 1,666 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

F2: These shares of common stock are held by a trust of which the reporting person is a trustee and beneficiary.